Rhythm Pharmaceuticals Inc
Company Profile
Business description
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Contact
222 Berkeley Street
12th Floor
BostonMA02116
USAT: +1 857 264-4280
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
414
Stocks News & Analysis
stocks
Why don’t good returns guarantee a 5-star rating?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,932.40 | 64.90 | -0.72% |
| CAC 40 | 8,218.62 | 1.84 | 0.02% |
| DAX 40 | 26,089.01 | 43.64 | 0.17% |
| Dow JONES (US) | 50,759.42 | 848.75 | -1.64% |
| FTSE 100 | 10,661.05 | 28.82 | -0.27% |
| HKSE | 23,294.75 | 213.42 | -0.91% |
| NASDAQ | 24,328.38 | 181.38 | -0.74% |
| Nikkei 225 | 59,024.28 | 163.85 | 0.28% |
| NZX 50 Index | 14,264.29 | 42.67 | -0.30% |
| S&P 500 | 7,340.53 | 76.06 | -1.03% |
| S&P/ASX 200 | 8,821.80 | 61.40 | -0.69% |
| SSE Composite Index | 3,587.83 | 3.25 | 0.09% |